Genmab — April 2022
-
ight months after teasing some positive topline results in previously untreated patients, Roche has yet to file for an approval because the FDA has requested to see more data on progression-free survival, according to Bill Anderson, CEO of Roche Pharmaceuticals.
-
Tror der står det samme her https://invesbrain.com/a-failure-in-breast-cancer-and-now-a-delay-for-polivy-roche-cant-catch-a-break/
-
God morgen.
-
Dagens finanskalender https://proinvestor.com/finanskalender
-
-
Fine ord og god omsætning. Mon Kesimpta når 1B i år?
-
-
Summary points from expert feedback:
Epcoritamab’s efficacy is impressive, especially since it is being tested as a single agent in advanced patients
KOL is not concerned by epcoritamab’s adverse event profile, believing rate of mostly mild cytokine release syndrome (CRS) is easily manageable
He believes epcoritamab has slight edge on rest of CD20xCD3 class, notably Roche’s glofitamab, given safety and ease of use -
Unless unexpected toxicities emerge, CD20xCD3 bispecifics may quickly move up from third- to first-line therapy in most if not all B-cell lymphomas
Penetration will be slower in community centres but he thinks they will solve the necessary logistical challenges within two years of launch
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind